Charles Theuer
CMO Halozyme
Seminars
Wednesday 5th November 2025
Exploring the Potential for Subcutaneous Delivery of ADCs
11:30 am
- Reviewing clinical use and benefits of recombinant human hyaluronidase PH20 (rHuPH20) and potential application to ADCs
- Demonstrating safe preclinical subcutaneous administration of an ADC
- Improving preclinical pharmacokinetics of ADCs delivered subcutaneously
